CBD-rich cannabis oil did not outperform placebo for knee pain
Effects and safety of a CBD-rich Cannabis sativa oil in knee osteoarthritis: a double-blind, randomized, placebo-controlled trial - CANOA - cannabis for osteoarthritis.
AI Summary
This double-blind, randomized, placebo-controlled human trial studied patients with knee osteoarthritis over 60 days. Participants received either placebo or a full-spectrum, CBD-rich Cannabis sativa oil containing 45 mg of CBD daily. The primary outcome was pain intensity measured with the WOMAC scale. Both groups improved, but the cannabis-oil group did not show a statistically significant advantage over placebo for pain.
The study also found no significant between-group differences in measures of pain, mood, sleep, or physical and mental quality of life. The oil was well tolerated: no serious adverse events or clinically significant changes in serum biomarkers were reported. However, this abstract does not provide the sample size or detailed numerical results, and it cannot establish whether other doses or formulations containing CBD, THC, or additional cannabinoids might be effective. This is an abstract-based summary, not a full-text review.
💡 Key Findings
📄
Original Abstract
Related Research
Similar Studies
More CBD research papers you might find interesting.
Modeling points to CYP2C19 as CBD’s key interaction concern
Review surveys nanocrystals for phytochemicals, including CBD, and their…
Review finds promise in acidic cannabinoids, but human benefits remain unproven
Explore More Research
Stay informed about the latest cannabis science.